Skip to content
10-Q

Quarterly Report

Kiniksa Pharmaceuticals International, plc KNSA

0001558370-25-005847

← back to feed
Filed
Apr 29, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Short Term Investments Q1 2025 · Mar 31, 2025 $111.21M
Short Term Investments Q1 2025 · Dec 31, 2024 $60.05M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $157.13M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $183.58M
Current Liabilities Q1 2025 · Mar 31, 2025 $97.27M
Current Liabilities Q1 2025 · Dec 31, 2024 $100.62M
Total Liabilities Q1 2025 · Mar 31, 2025 $141.84M
Total Liabilities Q1 2025 · Dec 31, 2024 $142.12M
Current Assets Q1 2025 · Mar 31, 2025 $355.91M
Current Assets Q1 2025 · Dec 31, 2024 $331.8M
Total Assets Q1 2025 · Mar 31, 2025 $599.33M
Total Assets Q1 2025 · Dec 31, 2024 $580.55M
Shares Diluted Q1 2025 · Mar 31, 2024 70.63M sh
Capex Q1 2025 · Mar 31, 2024 $84K
Operating Cash Flow Q1 2025 · Mar 31, 2024 $3.99M
Stockholders Equity Q1 2025 · Mar 31, 2024 $431.9M
Stockholders Equity Q1 2025 · Dec 31, 2023 $438.84M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.25
Eps Basic Q1 2025 · Mar 31, 2024 −$0.25
Sga Expense Q1 2025 · Mar 31, 2024 $38.68M
Rd Expense Q1 2025 · Mar 31, 2024 $26.33M
Net Income Q1 2025 · Mar 31, 2024 −$17.7M
Operating Income Q1 2025 · Mar 31, 2024 −$16.54M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $10.58M
Revenue Q1 2025 · Mar 31, 2024 $79.86M